Your shopping cart is currently empty

BChE/p38-α MAPK-IN-2 is a dual inhibitor of BChE and p38-α MAPK. It has an IC50 of 5.1 nM for hBChE and exhibits a 1000-fold selectivity over hAChE. Its IC50 for p38α MAPK is 8.12 μM. BChE/p38-α MAPK-IN-2 demonstrates neuroprotective properties, making it useful for research on neurological disorders such as Alzheimer's disease.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | BChE/p38-α MAPK-IN-2 is a dual inhibitor of BChE and p38-α MAPK. It has an IC50 of 5.1 nM for hBChE and exhibits a 1000-fold selectivity over hAChE. Its IC50 for p38α MAPK is 8.12 μM. BChE/p38-α MAPK-IN-2 demonstrates neuroprotective properties, making it useful for research on neurological disorders such as Alzheimer's disease. |
| Targets&IC50 | BCHE (human):5.1 nM |
| In vitro | BChE/p38-α MAPK-IN-2 (10-50 μM) exhibits no significant cytotoxicity in BV2 microglial cells. |
| In vivo | BChE/p38-α MAPK-IN-2, administered via intraperitoneal injection at a dosage of 5-10 mg/kg 60 minutes prior to testing, significantly enhances cognitive function in the Scopolamine-induced amnesia model in Albino Swiss (CD-1) mice. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.